Kuchinad, K. E., Kim, J. S., Woods, A., Leatherman, G., Gutierrez-Alamillo, L., Mayes, M. D., Domsic, R., Ramos, P. S., Silver, R. M., Varga, J., Saketkoo, L. A., Kafaja, S., Shanmugan, V. K., Gordon, J., Chung, L., Bernstein, E. J., Gourh, P., Boin, F., Kastner, D. L., … Shah, A. A. (2024). Racial variability in immune responses only partially explains differential systemic sclerosis disease severity. Annals of the Rheumatic Diseases, ard-2023-225458. https://doi.org/10.1136/ard-2023-225458

Barber, M. R. W., Ugarte-Gil, M. F., Hanly, J. G., Urowitz, M. B., St-Pierre, Y., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sanchez-Guerrero, J., Bernatsky, S., Wallace, D. J., Isenberg, D. A., Rahman, A., Merrill, J. T., Fortin, P. R., Gladman, D. D., Bruce, I. N., Petri, M., Ginzler, E. M., … Clarke, A. E. (2024). Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, ard-2024-225613. https://doi.org/10.1136/ard-2024-225613

Luo, Y., Ferrada, M. A., Sikora, K. A., Rankin, C., Alessi, H. D., Kastner, D. L., Deng, Z., Zhang, M., Merkel, P. A., Kraus, V. B., Allen, A. S., & Grayson, P. C. (2023). Ultra-rare genetic variation in relapsing polychondritis: a whole-exome sequencing study. Annals of the Rheumatic Diseases, 83(2), 253–260. https://doi.org/10.1136/ard-2023-224732

Baker, J. F., ODell, J. R., England, B. R., Giles, J. T., Newcomb, J. A., George, M. D., Thiele, G., Moreland, L., Bridges, S. L., Curtis, J. R., & Mikuls, T. R. (2024). Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis. Annals of the Rheumatic Diseases, 83(4), 429–436. https://doi.org/10.1136/ard-2023-225014

Askanase, A., Furie, R., Dall’era, M., Bomback, A., Schwarting, A., Zhao, M. H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R., Van Vollenhoven, R., & Urowitz, M. B. (2023). AB0531 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO LUPUS NEPHRITIS TREATMENTS FROM THE PUBLISHED LITERATURE. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.3897

Askanase, A., Stach, C., Brittain, C., Stojan, G., & Furie, R. (2023). POS0115 DAPIROLIZUMAB PEGOL EFFICACY BY SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A POST HOC ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.1991

Park, E., Daniel, L., Dickson, A., Corriere, M., Nepal, P., Hall, K., Plummer, D., Dupont, W., Murray, K., Stein, C. M., Ray, W., & Chung, C. (2023). POS0265 ASSOCIATION OF PREGABALIN VS GABAPENTIN WITH INCIDENT CONGESTIVE HEART FAILURE IN PATIENTS WITH NON-CANCER PAIN. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.2795

Askanase, A., Furie, R., Dall’era, M., Bomback, A., Schwarting, A., Zhao, M. H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R., Van Vollenhoven, R., & Urowitz, M. B. (2023). POS1153 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENTS FROM THE PUBLISHED LITERATURE. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.3052

Redmond, C. J., Kitakule, M. M., Son, A., Sylvester, M., Sacco, K., Delmonte, O., Licciardi, F., Castagnoli, R., Poli, M. C., Espinoza, Y., Astudillo, C., Weber, S. E., Montealegre Sanchez, G. A., Barron, K. S., Magliocco, M., Dobbs, K., Zhang, Y., Matthews, H., Oguz, C., … Schwartz, D. M. (2022). Deep immune profiling uncovers novel associations with clinical phenotypes of multisystem inflammatory syndrome in children (MIS-C). Annals of the Rheumatic Diseases, 82(3), 442–445. https://doi.org/10.1136/ard-2022-223269

Solomon, D. H., Giles, J. T., Liao, K. P., Ridker, P. M., Rist, P. M., Glynn, R. J., Broderick, R., Lu, F., Murray, M. T., Vanni, K., Santacroce, L. M., Abohashem, S., Robson, P. M., Fayad, Z., Mani, V., Tawakol, A., & Bathon, J. (2022). Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 82(3), 324–330. https://doi.org/10.1136/ard-2022-223302

Smolen, J. S., Landewé, R. B. M., Bergstra, S. A., Kerschbaumer, A., Sepriano, A., Aletaha, D., Caporali, R., Edwards, C. J., Hyrich, K. L., Pope, J. E., de Souza, S., Stamm, T. A., Takeuchi, T., Verschueren, P., Winthrop, K. L., Balsa, A., Bathon, J. M., Buch, M. H., Burmester, G. R., … van der Heijde, D. (2022). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases, 82(1), 3–18. https://doi.org/10.1136/ard-2022-223356

Charles-Schoeman, C., Buch, M. H., Dougados, M., Bhatt, D. L., Giles, J. T., Ytterberg, S. R., Koch, G. G., Vranic, I., Wu, J., Wang, C., Kwok, K., Menon, S., Rivas, J. L., Yndestad, A., Connell, C. A., & Szekanecz, Z. (2022). Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Annals of the Rheumatic Diseases, 82(1), 119–129. https://doi.org/10.1136/ard-2022-222259

Ugarte-Gil, M. F., Hanly, J., Urowitz, M., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sanchez-Guerrero, J., Bernatsky, S., Clarke, A. E., Wallace, D. J., Isenberg, D. A., Rahman, A., Merrill, J. T., Fortin, P. R., Gladman, D. D., Bruce, I. N., Petri, M., Ginzler, E. M., Dooley, M. A., … Alarcón, G. S. (2022). Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 81(11), 1541–1548. https://doi.org/10.1136/ard-2022-222487

Stern, L., Johnson, R., Shakouri, P., Athavale, A., Lamoreaux, B., Marder, B., & Mandayam, S. (2022). AB1050 CHARACTERISTICS OF PATIENTS WITH COINCIDENT GOUT AND ADVANCED CHRONIC KIDNEY DISEASE. Annals of the Rheumatic Diseases, 81, 1647–1648. https://doi.org/10.1136/annrheumdis-2022-eular.2489

Petri, M. A., Bertsias, G., Daniels, M., Fox, N. L., Hahn, B. H., Hammer, A., Harris, J., Quasny, H., Tani, C., & Askanase, A. (2022). POS0183 THE EFFECT OF BELIMUMAB ON SRI-4 RESPONSE IN MULTIPLE SUBGROUPS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS. Annals of the Rheumatic Diseases, 81, 323. https://doi.org/10.1136/annrheumdis-2022-eular.1807

Ozdede, A., Güner, S., Ozcifci, G., Yurttas, B., Toker Dincer, Z., Atli, Z., Uygunoglu, U., Durmaz, E., Ucar, D., Ugurlu, S., Saip, S., Tabak, Ö. F., Hamuryudan, V., & Seyahi, E. (2022). POS1255 SAFETY OF THE PFIZER/BIONTECH AND SINOVAC/CORONAVAC VACCINES AMONG PATIENTS WITH BEHCET’S SYNDROME AND FAMILIAL MEDITERRANEAN FEVER. Annals of the Rheumatic Diseases, 81, 962–963. https://doi.org/10.1136/annrheumdis-2022-eular.3711

Almeida-Brasil, C. C., Hanly, J. G., Urowitz, M., Clarke, A. E., Ruiz-Irastorza, G., Gordon, C., Ramsey-Goldman, R., Petri, M., Ginzler, E. M., Wallace, D. J., Bae, S.-C., Romero-Diaz, J., Dooley, M. A., Peschken, C., Isenberg, D., Rahman, A., Manzi, S., Jacobsen, S., Lim, S., … Bernatsky, S. (2022). Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 81(3), 370–378. https://doi.org/10.1136/annrheumdis-2021-221295